Smith & Nephew PLC (LSE:SN) efforts to expand its surgical robotics platform and strengthen its orthopaedics pipeline received a vote of confidence from surgeons at a recent investor event, according to analysts at JPMorgan.
Analyst Veronika Dubajova said discussions at the medical technology group's Expert Surgeon Insights event in London left her incrementally more positive on the prospects for CORI, Smith & Nephew's robotic-assisted surgery platform.
The event featured surgeons discussing their experiences with products across the company's portfolio and followed a similar gathering held in New York in December.
Dubajova said enthusiasm for CORI appeared to have increased as the platform broadens beyond knee procedures. The addition of CORI Shoulder has already expanded its capabilities, while a hip surgery application is expected to launch within the next six to seven months.
Surgeons also expressed growing confidence in LANDMARK, Smith & Nephew's next-generation knee system, ahead of its planned launch in the third quarter of 2026.
The positive feedback is significant because investors have closely watched Smith & Nephew's ability to drive growth through innovation after years of lagging some larger rivals in orthopaedics.
JPMorgan said the event highlighted the breadth of the group's product development programme and the pace of upcoming launches.
However, Dubajova noted that investors remain focused on nearer-term execution, particularly delivery against the company's 2026 guidance, which is weighted towards the second half of the year.
